Announcement • Jul 31
Neurothera Labs Demonstrates End-To-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics NeuroThera Labs announced another technological milestone achieved by NeuroThera’s quantum sampling workflow platform for clinical trials data analytics. The Platform has successfully demonstrated a complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data through a fully integrated analytical framework, from secure data ingestion and preparation, through quantum-enabled analytical processing, to the generation of biologically and clinically interpretable insights. The workflow was executed within a quantum simulation environment designed to emulate quantum computational processes relevant to the Platform's analytical architecture. The Platform's proprietary analytical framework is designed to enable quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses of clinical trial and biomedical datasets. This milestone confirms that the Platform can support a complete hybrid quantum-classical analytical workflow designed to address complex, high-dimensional biomedical datasets while applying quantum-inspired and quantum-enabled methodologies to uncover non-obvious patterns, all while maintaining alignment with downstream scientific interpretation requirements. The Platform is being advanced through CliniQuantum Ltd., a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%. Announcement • Jul 29
NeuroThera Labs Inc Advances Quantum Platform for Clinical Data Analytics on A Platform of an S&P 500 Company NeuroThera Labs Inc. has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis. The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500 company platform for hybrid quantum-classical computing. The validation supports a key component of the Platform's computational architecture and is expected to further expand the Platform’s capabilities for addressing complex analytical challenges involving large-scale clinical and biomedical datasets. Many real-world challenges in healthcare, life sciences, drug development and advanced analytics are naturally represented as continuous probability distributions. The Platform’s proprietary methodology converts these continuous datasets into quantum-operable energy landscape representations, enabling the application of Quantum Markov Chain Monte Carlo techniques while preserving the statistical characteristics of the original data. By using the Platform, quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture enables continuous datasets to be explored through quantum-generated proposals while maintaining established statistical guarantees. The validated workflow represents an important step toward enabling increasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve. The Platform is being advanced through CliniQuantum, a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%. Announcement • Jul 15
Neurothera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome NeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects. In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events. 
